Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors

Fabio Efficace, Gianantonio Rosti, Francesco Cottone, Massimo Breccia, Fausto Castagnetti, Alessandra Iurlo, Franco Mandelli, Michele Baccarani

Research output: Contribution to journalArticlepeer-review

Abstract

The main objective of this study was to outline key characteristics, including health-related quality of life (HRQOL) and symptoms, in 175 chronic myeloid leukemia (CML) patients reporting intentional or unintentional reasons for not fully adhering to imatinib therapy. There was a significant higher proportion of males in the unintentional group (P= 0.037). Also, in this group patients were on average younger (P= 0.046). Patients reporting intentional reasons had generally a worse HRQOL profile and a higher symptom severity than those who reported unintentional reasons for non-adherence. This study suggests that patients with suboptimal adherence are not a homogenous group, thus generalized approaches to improve medication-taking behaviors are not recommended.

Original languageEnglish
Pages (from-to)294-298
Number of pages5
JournalLeukemia Research
Volume38
Issue number3
DOIs
Publication statusPublished - Mar 2014

Keywords

  • Adherence to therapy
  • Chronic myeloid leukemia
  • Quality of life
  • Symptoms

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this